{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T15:36:19Z","timestamp":1782488179464,"version":"3.54.5"},"reference-count":57,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T00:00:00Z","timestamp":1788048000000},"content-version":"am","delay-in-days":333,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"NIH NCI","doi-asserted-by":"publisher","award":["T32 CA101642"],"award-info":[{"award-number":["T32 CA101642"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001700","name":"Ministry of Education, Culture, Sports, Science and Technology","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001700","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004917","name":"Cancer Prevention and Research Institute of Texas","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004917","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006264","name":"RIKEN","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006264","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.ygyno.2025.08.024","type":"journal-article","created":{"date-parts":[[2025,8,30]],"date-time":"2025-08-30T13:03:08Z","timestamp":1756558988000},"page":"152-159","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Efficacy of cyclin-dependent kinase 4\/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models"],"prefix":"10.1016","volume":"201","author":[{"given":"Allison L","family":"Brodsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Welte","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena K","family":"Vuttaradhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elio","family":"Tahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Khlebus","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Celestino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reid T","family":"Powell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clifford C","family":"Stephan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nghi","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yimin","family":"Geng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiro","family":"Takamatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Calzoncinth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren","family":"Cobb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M","family":"Gershenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barrett","family":"Lawson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Tyler","family":"Hillman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.ygyno.2025.08.024_bb0005","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1200\/JCO.2003.10.019","article-title":"Granulosa cell tumor of the ovary","volume":"21","author":"Schumer","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2025.08.024_bb0010","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1056\/NEJMoa0902542","article-title":"Mutation of FOXL2 in granulosa-cell tumors of the ovary","volume":"360","author":"Shah","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0015","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/bjc.2013.241","article-title":"Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary","volume":"109","author":"Mangili","year":"2013","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.ygyno.2025.08.024_bb0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2024.01.002","article-title":"Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors","author":"How","year":"2024","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.024_bb0025","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ygyno.2005.01.011","article-title":"The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors","volume":"97","author":"Brown","year":"2005","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.08.024_bb0030","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/0029-7844(95)00491-2","article-title":"Treatment of poor-prognosis sex cord-stromal tumors of the ovary with the combination of bleomycin, etoposide, and cisplatin","volume":"87","author":"Gershenson","year":"1996","journal-title":"Obstet. Gynecol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.08.024_bb0035","doi-asserted-by":"crossref","first-page":"1923","DOI":"10.1001\/jamaoncol.2020.4574","article-title":"Effect of weekly paclitaxel with or without bevacizumab on progression-free rate among patients with relapsed ovarian sex cord-stromal Tumors: the ALIENOR\/ENGOT-ov7 randomized clinical trial","volume":"6","author":"Ray-Coquard","year":"2020","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.024_bb0040","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1006\/gyno.1998.5304","article-title":"Bleomycin, etoposide, and cisplatin combination therapy of ovarian granulosa cell tumors and other stromal malignancies: a gynecologic oncology group study","volume":"72","author":"Homesley","year":"1999","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0045","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ygyno.2021.07.024","article-title":"A phase 2 study of anastrozole in patients with oestrogen receptor and\/progesterone receptor positive recurrent\/metastatic granulosa cell tumours\/sex-cord stromal tumours of the ovary: the PARAGON\/ANZGOG 0903 trial","volume":"163","author":"Banerjee","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0050","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.ygyno.2014.03.573","article-title":"Hormone therapy in ovarian granulosa cell tumors: a systematic review","volume":"134","author":"van Meurs","year":"2014","journal-title":"Gynecol. Oncol."},{"issue":"6","key":"10.1016\/j.ygyno.2025.08.024_bb0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2023.02.029","article-title":"Clinical outcomes of leuprolide acetate in the treatment of recurrent ovarian granulosa cell tumors","volume":"228","author":"Foster","year":"2023","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.024_bb0060","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1007\/s10637-020-01043-9","article-title":"The clinical efficacy and safety of single-agent pembrolizumab in patients with recurrent granulosa cell tumors of the ovary: a case series from a phase II basket trial","volume":"39","author":"How","year":"2021","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ygyno.2025.08.024_bb0065","first-page":"OF1","article-title":"SWOG\/NCI phase II dual anti-CTLA-4\/PD-1 blockade in rare tumors (DART): non-epithelial ovarian cancer","author":"Chae","year":"2024","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.024_bb0070","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ygyno.2021.06.024","article-title":"Prevalence of predictive biomarkers in a large cohort of molecularly defined adult-type ovarian granulosa cell tumors","volume":"162","author":"Hillman","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0075","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1158\/1541-7786.MCR-18-0359","article-title":"Mutational landscape of ovarian adult granulosa cell Tumors from whole exome and targeted TERT promoter sequencing","volume":"17","author":"Alexiadis","year":"2019","journal-title":"Mol. Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.024_bb0080","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s12672-011-0069-3","article-title":"Nuclear receptor profiling of ovarian granulosa cell tumors","volume":"2","author":"Alexiadis","year":"2011","journal-title":"Horm. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.024_bb0085","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1210\/endo.138.3.5002","article-title":"Estrogen induces early and timed activation of cyclin-dependent kinases 4, 5, and 6 and increases cyclin messenger ribonucleic acid expression in rat uterus","volume":"138","author":"Altucci","year":"1997","journal-title":"Endocrinology"},{"issue":"3","key":"10.1016\/j.ygyno.2025.08.024_bb0090","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1200\/JCO.18.01624","article-title":"Randomized phase II study evaluating palbociclib in addition to letrozole as neoadjuvant therapy in estrogen receptor-positive early breast cancer: PALLET trial","volume":"37","author":"Johnston","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.ygyno.2025.08.024_bb0095","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1093\/annonc\/mdy448","article-title":"Letrozole and palbociclib versus chemotherapy as neoadjuvant therapy of high-risk luminal breast cancer","volume":"29","author":"Cottu","year":"2018","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.024_bb0100","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S1470-2045(20)30642-2","article-title":"Palbociclib with adjuvant endocrine therapy in early breast cancer (PALLAS): interim analysis of a multicentre, open-label, randomised, phase 3 study","volume":"22","author":"Mayer","year":"2021","journal-title":"Lancet Oncol."},{"issue":"34","key":"10.1016\/j.ygyno.2025.08.024_bb0105","doi-asserted-by":"crossref","first-page":"3987","DOI":"10.1200\/JCO.20.02514","article-title":"Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR+, HER2-, node-positive, high-risk, early breast cancer (monarchE)","volume":"38","author":"Johnston","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2025.08.024_bb0110","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1056\/NEJMoa1607303","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn","year":"2016","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2025.08.024_bb0115","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1200\/JCO.24.00144","article-title":"Final results of RIGHT choice: Ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor-positive\/human epidermal growth factor receptor 2-negative advanced breast cancer","volume":"42","author":"Lu","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2025.08.024_bb0120","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"32","key":"10.1016\/j.ygyno.2025.08.024_bb0125","doi-asserted-by":"crossref","first-page":"3638","DOI":"10.1200\/JCO.2017.75.6155","article-title":"MONARCH 3: Abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.024_bb0130","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.ygyno.2012.10.013","article-title":"Quantification of ER\/PR expression in ovarian low-grade serous carcinoma","volume":"128","author":"Escobar","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"16_suppl","key":"10.1016\/j.ygyno.2025.08.024_bb0135","doi-asserted-by":"crossref","first-page":"5522","DOI":"10.1200\/JCO.2022.40.16_suppl.5522","article-title":"A pilot phase II study of neoadjuvant fulvestrant plus abemaciclib in women with advanced low-grade serous carcinoma","volume":"40","author":"Cobb","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2025.08.024_bb0140","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/j.ygyno.2023.06.466","article-title":"GOG 3026 a phase II trial of letrozole + ribociclib in women with recurrent low-grade serous carcinoma of the ovary, fallopian tube or peritoneum: a GOG foundation study (001)","volume":"176","author":"Slomovitz","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"24","key":"10.1016\/j.ygyno.2025.08.024_bb0145","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"9","key":"10.1016\/j.ygyno.2025.08.024_bb0150","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1038\/s41417-024-00747-x","article-title":"Recent progress of CDK4\/6 inhibitors\u2019 current practice in breast cancer","volume":"31","author":"Wang","year":"2024","journal-title":"Cancer Gene Ther."},{"issue":"5","key":"10.1016\/j.ygyno.2025.08.024_bb0155","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1038\/s41591-019-0422-6","article-title":"An organoid platform for ovarian cancer captures intra- and interpatient heterogeneity","volume":"25","author":"Kopper","year":"2019","journal-title":"Nat. Med."},{"issue":"5","key":"10.1016\/j.ygyno.2025.08.024_bb0160","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1158\/0008-5472.CAN-24-2341","article-title":"Gain-of-function chromatin remodeling activity of oncogenic FOXL2-C134W reprograms glucocorticoid receptor occupancy to drive granulosa cell tumors","volume":"85","author":"Welte","year":"2024","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0165","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1210\/endo.142.1.7862","article-title":"Establishment and characterization of a steroidogenic human granulosa-like tumor cell line, KGN, that expresses functional follicle-stimulating hormone receptor","volume":"142","author":"Nishi","year":"2001","journal-title":"Endocrinology"},{"issue":"6","key":"10.1016\/j.ygyno.2025.08.024_bb0170","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.3853","article-title":"Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs","volume":"13","author":"Hafner","year":"2016","journal-title":"Nat. Methods"},{"issue":"101297","key":"10.1016\/j.ygyno.2025.08.024_bb0175","article-title":"Efficacy of cyclin-dependent kinase 4\/6 inhibitors in combination with hormonal therapy in patients with recurrent granulosa cell tumor of the ovary: a case series","volume":"50","author":"Albright","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2025.08.024_bb0180","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.ygyno.2023.05.040","article-title":"P13 ovarian granulosa cell tumors treated with estrogen blockade and CDK4\/6 inhibitors: a case series","volume":"173","author":"Nanez","year":"2023","journal-title":"Gynecol. Oncol."},{"issue":"4","key":"10.1016\/j.ygyno.2025.08.024_bb0185","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1136\/ijgc-2023-005189","article-title":"A phase II, multicenter, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer: ALEPRO trial","volume":"34","author":"Ottenbourgs","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0190","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1158\/2159-8290.CD-18-0830","article-title":"PTEN loss mediates clinical cross-resistance to CDK4\/6 and PI3K\u03b1 inhibitors in breast cancer","volume":"10","author":"Costa","year":"2020","journal-title":"Cancer Discov."},{"key":"10.1016\/j.ygyno.2025.08.024_bb0195","series-title":"Data From the Genomic Landscape of Intrinsic and Acquired Resistance to Cyclin-Dependent Kinase 4\/6 Inhibitors in Patients With Hormone Receptor\u2013Positive Metastatic Breast Cancer","author":"Wander","year":"2023"},{"issue":"18","key":"10.1016\/j.ygyno.2025.08.024_bb0200","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1158\/1078-0432.CCR-17-0369","article-title":"Single-cell dynamics determines response to CDK4\/6 inhibition in triple-negative breast cancer","volume":"23","author":"Asghar","year":"2017","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0205","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41523-018-0092-4","article-title":"Cyclin E1 and Rb modulation as common events at time of resistance to palbociclib in hormone receptor-positive breast cancer","volume":"4","author":"Guarducci","year":"2018","journal-title":"NPJ Breast Cancer."},{"issue":"15_suppl","key":"10.1016\/j.ygyno.2025.08.024_bb0210","doi-asserted-by":"crossref","first-page":"3519","DOI":"10.1200\/JCO.2020.38.15_suppl.3519","article-title":"Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy","volume":"38","author":"Goetz","year":"2020","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.ygyno.2025.08.024_bb0215","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/onc.2016.379","article-title":"Acquired CDK6 amplification promotes breast cancer resistance to CDK4\/6 inhibitors and loss of ER signaling and dependence","volume":"36","author":"Yang","year":"2017","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.ygyno.2025.08.024_bb0220","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1016\/j.ccell.2018.11.006","article-title":"Loss of the FAT1 tumor suppressor promotes resistance to CDK4\/6 inhibitors via the hippo pathway","volume":"34","author":"Li","year":"2018","journal-title":"Cancer Cell"},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10549-019-05365-y","article-title":"Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4\/6 inhibitors in metastatic breast cancer patients","volume":"178","author":"Del Re","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"issue":"22","key":"10.1016\/j.ygyno.2025.08.024_bb0230","doi-asserted-by":"crossref","first-page":"12292","DOI":"10.3390\/ijms222212292","article-title":"Resistance to CDK4\/6 inhibitors in estrogen receptor-positive breast cancer","volume":"22","author":"Scheidemann","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0235","doi-asserted-by":"crossref","first-page":"R15","DOI":"10.1530\/ERC-18-0317","article-title":"Overcoming CDK4\/6 inhibitor resistance in ER-positive breast cancer","volume":"26","author":"Portman","year":"2019","journal-title":"Endocr. Relat. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2025.08.024_bb0240","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1038\/s41588-018-0287-5","article-title":"Acquired HER2 mutations in ER+ metastatic breast cancer confer resistance to estrogen receptor-directed therapies","volume":"51","author":"Nayar","year":"2019","journal-title":"Nat. Genet."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0245","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s41698-019-0090-5","article-title":"Blood-based monitoring identifies acquired and targetable driver HER2 mutations in endocrine-resistant metastatic breast cancer","volume":"3","author":"Medford","year":"2019","journal-title":"NPJ Precis Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2025.08.024_bb0250","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1158\/2159-8290.CD-18-0264","article-title":"The genetic landscape and clonal evolution of breast cancer resistance to palbociclib plus fulvestrant in the PALOMA-3 trial","volume":"8","author":"O\u2019Leary","year":"2018","journal-title":"Cancer Discov."},{"issue":"14","key":"10.1016\/j.ygyno.2025.08.024_bb0255","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1200\/JCO.18.00925","article-title":"Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer","volume":"37","author":"Turner","year":"2019","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0260","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1186\/s12943-022-01642-5","article-title":"S6K1 amplification confers innate resistance to CDK4\/6 inhibitors through activating c-Myc pathway in patients with estrogen receptor-positive breast cancer","volume":"21","author":"Mo","year":"2022","journal-title":"Mol. Cancer"},{"issue":"11","key":"10.1016\/j.ygyno.2025.08.024_bb0265","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1016\/j.annonc.2023.08.011","article-title":"Pooled ctDNA analysis of MONALEESA phase III advanced breast cancer trials","volume":"34","author":"Andr\u00e9","year":"2023","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0270","doi-asserted-by":"crossref","first-page":"5258","DOI":"10.1038\/s41467-022-32828-6","article-title":"High p16 expression and heterozygous RB1 loss are biomarkers for CDK4\/6 inhibitor resistance in ER+ breast cancer","volume":"13","author":"Palafox","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ygyno.2025.08.024_bb0275","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2024-005837","article-title":"TERT promoter mutations and survival outcomes in adult-type granulosa cell tumors","author":"Brodsky","year":"2025","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2025.08.024_bb0280","doi-asserted-by":"crossref","first-page":"2496","DOI":"10.1038\/s41467-018-04950-x","article-title":"KMT2D\/MLL2 inactivation is associated with recurrence in adult-type granulosa cell tumors of the ovary","volume":"9","author":"Hillman","year":"2018","journal-title":"Nat. Commun."},{"issue":"5","key":"10.1016\/j.ygyno.2025.08.024_bb0285","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1158\/1541-7786.MCR-22-0623","article-title":"Comparative tumor microenvironment analysis of primary and recurrent ovarian granulosa cell Tumors","volume":"21","author":"Khlebus","year":"2023","journal-title":"Mol. Cancer Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825009746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825825009746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T00:38:23Z","timestamp":1762562303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825825009746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":57,"alternative-id":["S0090825825009746"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.08.024","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of cyclin-dependent kinase 4\/6 inhibitors in preclinical adult-type ovarian granulosa cell tumor models","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2025.08.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}